Radiotherapy Planning Using Fluciclovine PET in Patients With Newly

Status Recruiting

Clinical Trial Summary

The purpose of the this study is to see if the use of a PET scan with 18F-fluciclovine (PET or Fluciclovine PET) in addition to the normal radiation planning imaging procedures (MRI and CT scan) will help determine the areas where the radiation therapy is to be delivered. It is also a goal of the study to determine if subjects live longer when treatment plans for radiation therapy are designed using a Fluciclovine PET scan, as well as MRI and CT scans. We will also collect information on if and where the tumor returns. Information on the side effects from the two different treatment planning imaging methods will also be collected. 18F-Fluciclovine is an FDA-approved radioactive diagnostic agent that is injected into the patient and then taken up by cancer cells, which can then be visualized with a PET/CT scan. 18F-Fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is still investigational for the purposes of this study.

Clinical Trial Description

The goal of this study is to see if the use of PET in planning radiotherapy can reduce these local failures. Glioblastoma (GBM) is the most common primary malignant brain tumor. Newly diagnosed glioblastoma management includes maximum safe resection followed by radiotherapy with concurrent temozolomide, followed by maintenance temozolomide for 6 - 12 cycles. This postoperative chemoradiotherapy approach has resulted in a significant increase in median PFS (5.0 vs. 6.9 months) and OS (12.1 vs. 14.6 months) compared to radiotherapy alone (Stupp 2005). However, despite such multi-modality therapy, the median survival for GBM remains poor at approximately 15-16 months in contemporary series (Grossman, Ye et al. 2010, Gilbert, Wang et al. 2013 vs 2010). Recently, a randomized trial of tumor-treating fields (TTF or Optune) plus temozolomide demonstrated the benefit of this treatment in newly diagnosed glioblastoma that led to FDA approval of the device (Stupp 2015, Stupp 2017). However despite these advances, most patients still have a poor prognosis with median survival of 16-21 months. Although adjuvant chemoradiotherapy has been shown to increase survival, a predominant pattern of failure remains local (Chan, Lee et al. 2002, Milano, Okunieff et al. 2010). Therefore, better therapeutic options are needed for this disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04840069
Study type	Interventional
Source	St. Joseph's Hospital and Medical Center, Phoenix
Contact	Phase 0 Navigator
Phone	602-406-8605
Email	research@ivybraintumorcenter.org
Status	Recruiting
Phase	Phase 2
Start date	June 7, 2021
Completion date	March 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03899857` - Pembrolizumab for Newly Diagnosed Glioblastoma	Phase 2
Active, not recruiting	`NCT05163080` - SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)	Phase 2
Active, not recruiting	`NCT04474353` - Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma	Phase 1
Recruiting	`NCT05235737` - The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab	Phase 4
Active, not recruiting	`NCT03400917` - Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma	Phase 2
Completed	`NCT03619239` - Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma	Phase 1
Completed	`NCT03345095` - A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma	Phase 3
Recruiting	`NCT04478279` - A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05864534` - Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma	Phase 2
Not yet recruiting	`NCT04967690` - A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM	Phase 1
Active, not recruiting	`NCT04600817` - A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)	Phase 2
Active, not recruiting	`NCT03782415` - Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT04477200` - Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma	Phase 1
Withdrawn	`NCT04065087` - Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT05380349` - Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms